Cetuximab as third‐line rechallenge plus either irinotecan or avelumab is an effective treatment in metastatic colorectal cancer patients with baseline plasma RAS/BRAF wild‐type circulating tumor DNA: Individual patient data pooled analysis of CRICKET and CAVE trials

Abstract The rechallenge strategy is based on the concept that a subset of patients with RAS wild‐type (WT) metastatic colorectal cancer (mCRC) could still benefit of epidermal growth factor receptor (EGFR) inhibition, after progression to an anti‐EGFR based‐therapy. We performed a pooled analysis o...

Täydet tiedot

Bibliografiset tiedot

Päätekijät:	G. Martini, D. Ciardiello, V. Famiglietti, D. Rossini, C. Antoniotti, T. Troiani, S. Napolitano, L. Esposito, T. P. Latiano, E. Maiello, M. Del Re, S. Lonardi, G. Aprile, D. Santini, G. Masi, A. Avallone, N. Normanno, F. Pietrantonio, C. Pinto, F. Ciardiello, C. Cremolini, E. Martinelli
Aineistotyyppi:	Artigo
Kieli:	Inglês
Julkaistu:	Wiley 2023-04-01
Sarja:	Cancer Medicine
Aiheet:	cetuximab immunotherapy metastatic colorectal cancer rechallenge
Linkit:	https://doi.org/10.1002/cam4.5699
Tagit:	Lisää tagi Ei tageja, Lisää ensimmäinen tagi!